Loading…
Malaria chemoprophylaxis with tafenoquine: a randomised study
Tafenoquine is an analogue of primaquine with an improved therapeutic and safety profile. It has a long half-life and activity against liver-stage malaria parasites, so may be useful for chemoprophylaxis. In this randomised, double-blind study we assessed the efficacy and safety of tafenoquine in di...
Saved in:
| Published in: | The Lancet (British edition) 2000-06, Vol.355 (9220), p.2041-2045 |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c388t-2540680816bf3e94571134723ffbb10def548ab4dd356f0709732aee4226a1993 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c388t-2540680816bf3e94571134723ffbb10def548ab4dd356f0709732aee4226a1993 |
| container_end_page | 2045 |
| container_issue | 9220 |
| container_start_page | 2041 |
| container_title | The Lancet (British edition) |
| container_volume | 355 |
| creator | Lell, Bertrand Faucher, Jean-François Missinou, Michel Anoumou Borrmann, Steffen Dangelmaier, Oliver Horton, John Kremsner, Peter G |
| description | Tafenoquine is an analogue of primaquine with an improved therapeutic and safety profile. It has a long half-life and activity against liver-stage malaria parasites, so may be useful for chemoprophylaxis. In this randomised, double-blind study we assessed the efficacy and safety of tafenoquine in different doses.
2144 individuals aged 12–20 years living in Lambaréné, Gabon, an endemic area for
Plasmodium falciparum malaria, were invited to take part. 535 attended, and 426 eligible participants were randomly assigned tafenoquine (250 mg, 125mg, 62·5 mg, or 31·25 mg) or placebo daily for 3 days. 417 received initial curative treatment with halofantrine, and 410 completed the assigned prophylaxis regimen. During follow-up of 70 days, adverse events were recorded and thick blood smears were examined weekly. The primary and secondary endpoints were the number of individuals with positive blood smears by day 56 and day 77, respectively. Analyses were per-protocol.
Eight positive blood smears were recorded by day 56 (four/82 participants in the placebo group; four/79 tafenoquine 31·25 mg group). By day 77, 34 positive blood smears had been recorded (14/82 placebo; 16/79 tafenoquine 31·25 mg; three/86 tafenoquine 62·5 mg; one/79 tafenoquine 125 mg; none/84 tafenoquine 250 mg). Numbers of adverse events did not differ significantly between the treatment groups.
Tafenoquine is effective and well tolerated. It has the potential to replace currently used drugs for malaria chemoprophylaxis. |
| doi_str_mv | 10.1016/S0140-6736(00)02352-7 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_199031831</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0140673600023527</els_id><sourcerecordid>55139310</sourcerecordid><originalsourceid>FETCH-LOGICAL-c388t-2540680816bf3e94571134723ffbb10def548ab4dd356f0709732aee4226a1993</originalsourceid><addsrcrecordid>eNqFkE1Lw0AQhhdRbK3-BCV40kN0NrubTQQRKX5BxYMK3pZNdkK3NEm7m6j996ZNEW-e5jDPOx8PIccULijQ-PIVKIcwliw-AziHiIkolDtkSLnkoeDyY5cMf5EBOfB-BgA8BrFPBhSSRDARD8n1s55rZ3WQT7GsF65eTFdz_W198GWbadDoAqt62doKrwIdOF2ZurQeTeCb1qwOyV6h5x6PtnVE3u_v3saP4eTl4Wl8OwlzliRNGAkOcQIJjbOCYcqFpJRxGbGiyDIKBgvBE51xY7qbCpCQShZpRB5FsaZpykbktJ_bHbhs0TdqVreu6laqrg2MJox2kOih3NXeOyzUwtlSu5WioNbO1MaZWgtRAGrjTMkud7Id3mYlmj-pXlIH3PQAdi9-WnTK5xarHI11mDfK1PafFT_vQXoq</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>199031831</pqid></control><display><type>article</type><title>Malaria chemoprophylaxis with tafenoquine: a randomised study</title><source>Business Source Ultimate</source><source>ScienceDirect Freedom Collection 2022-2024</source><creator>Lell, Bertrand ; Faucher, Jean-François ; Missinou, Michel Anoumou ; Borrmann, Steffen ; Dangelmaier, Oliver ; Horton, John ; Kremsner, Peter G</creator><creatorcontrib>Lell, Bertrand ; Faucher, Jean-François ; Missinou, Michel Anoumou ; Borrmann, Steffen ; Dangelmaier, Oliver ; Horton, John ; Kremsner, Peter G</creatorcontrib><description>Tafenoquine is an analogue of primaquine with an improved therapeutic and safety profile. It has a long half-life and activity against liver-stage malaria parasites, so may be useful for chemoprophylaxis. In this randomised, double-blind study we assessed the efficacy and safety of tafenoquine in different doses.
2144 individuals aged 12–20 years living in Lambaréné, Gabon, an endemic area for
Plasmodium falciparum malaria, were invited to take part. 535 attended, and 426 eligible participants were randomly assigned tafenoquine (250 mg, 125mg, 62·5 mg, or 31·25 mg) or placebo daily for 3 days. 417 received initial curative treatment with halofantrine, and 410 completed the assigned prophylaxis regimen. During follow-up of 70 days, adverse events were recorded and thick blood smears were examined weekly. The primary and secondary endpoints were the number of individuals with positive blood smears by day 56 and day 77, respectively. Analyses were per-protocol.
Eight positive blood smears were recorded by day 56 (four/82 participants in the placebo group; four/79 tafenoquine 31·25 mg group). By day 77, 34 positive blood smears had been recorded (14/82 placebo; 16/79 tafenoquine 31·25 mg; three/86 tafenoquine 62·5 mg; one/79 tafenoquine 125 mg; none/84 tafenoquine 250 mg). Numbers of adverse events did not differ significantly between the treatment groups.
Tafenoquine is effective and well tolerated. It has the potential to replace currently used drugs for malaria chemoprophylaxis.</description><identifier>ISSN: 0140-6736</identifier><identifier>EISSN: 1474-547X</identifier><identifier>DOI: 10.1016/S0140-6736(00)02352-7</identifier><identifier>PMID: 10885356</identifier><identifier>CODEN: LANCAO</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Adolescent ; Adult ; Aminoquinolines - administration & dosage ; Aminoquinolines - adverse effects ; Aminoquinolines - therapeutic use ; Antimalarials - administration & dosage ; Antimalarials - adverse effects ; Antimalarials - therapeutic use ; Child ; Dose-Response Relationship, Drug ; Double-Blind Method ; Drug Administration Schedule ; Drug therapy ; Female ; Gabon ; Humans ; Malaria ; Malaria, Falciparum - blood ; Malaria, Falciparum - drug therapy ; Malaria, Falciparum - prevention & control ; Male ; Phenanthrenes - therapeutic use</subject><ispartof>The Lancet (British edition), 2000-06, Vol.355 (9220), p.2041-2045</ispartof><rights>2000 Elsevier Ltd</rights><rights>Copyright Lancet Ltd. Jun 10, 2000</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c388t-2540680816bf3e94571134723ffbb10def548ab4dd356f0709732aee4226a1993</citedby><cites>FETCH-LOGICAL-c388t-2540680816bf3e94571134723ffbb10def548ab4dd356f0709732aee4226a1993</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,786,790,27957,27958</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10885356$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lell, Bertrand</creatorcontrib><creatorcontrib>Faucher, Jean-François</creatorcontrib><creatorcontrib>Missinou, Michel Anoumou</creatorcontrib><creatorcontrib>Borrmann, Steffen</creatorcontrib><creatorcontrib>Dangelmaier, Oliver</creatorcontrib><creatorcontrib>Horton, John</creatorcontrib><creatorcontrib>Kremsner, Peter G</creatorcontrib><title>Malaria chemoprophylaxis with tafenoquine: a randomised study</title><title>The Lancet (British edition)</title><addtitle>Lancet</addtitle><description>Tafenoquine is an analogue of primaquine with an improved therapeutic and safety profile. It has a long half-life and activity against liver-stage malaria parasites, so may be useful for chemoprophylaxis. In this randomised, double-blind study we assessed the efficacy and safety of tafenoquine in different doses.
2144 individuals aged 12–20 years living in Lambaréné, Gabon, an endemic area for
Plasmodium falciparum malaria, were invited to take part. 535 attended, and 426 eligible participants were randomly assigned tafenoquine (250 mg, 125mg, 62·5 mg, or 31·25 mg) or placebo daily for 3 days. 417 received initial curative treatment with halofantrine, and 410 completed the assigned prophylaxis regimen. During follow-up of 70 days, adverse events were recorded and thick blood smears were examined weekly. The primary and secondary endpoints were the number of individuals with positive blood smears by day 56 and day 77, respectively. Analyses were per-protocol.
Eight positive blood smears were recorded by day 56 (four/82 participants in the placebo group; four/79 tafenoquine 31·25 mg group). By day 77, 34 positive blood smears had been recorded (14/82 placebo; 16/79 tafenoquine 31·25 mg; three/86 tafenoquine 62·5 mg; one/79 tafenoquine 125 mg; none/84 tafenoquine 250 mg). Numbers of adverse events did not differ significantly between the treatment groups.
Tafenoquine is effective and well tolerated. It has the potential to replace currently used drugs for malaria chemoprophylaxis.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aminoquinolines - administration & dosage</subject><subject>Aminoquinolines - adverse effects</subject><subject>Aminoquinolines - therapeutic use</subject><subject>Antimalarials - administration & dosage</subject><subject>Antimalarials - adverse effects</subject><subject>Antimalarials - therapeutic use</subject><subject>Child</subject><subject>Dose-Response Relationship, Drug</subject><subject>Double-Blind Method</subject><subject>Drug Administration Schedule</subject><subject>Drug therapy</subject><subject>Female</subject><subject>Gabon</subject><subject>Humans</subject><subject>Malaria</subject><subject>Malaria, Falciparum - blood</subject><subject>Malaria, Falciparum - drug therapy</subject><subject>Malaria, Falciparum - prevention & control</subject><subject>Male</subject><subject>Phenanthrenes - therapeutic use</subject><issn>0140-6736</issn><issn>1474-547X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><recordid>eNqFkE1Lw0AQhhdRbK3-BCV40kN0NrubTQQRKX5BxYMK3pZNdkK3NEm7m6j996ZNEW-e5jDPOx8PIccULijQ-PIVKIcwliw-AziHiIkolDtkSLnkoeDyY5cMf5EBOfB-BgA8BrFPBhSSRDARD8n1s55rZ3WQT7GsF65eTFdz_W198GWbadDoAqt62doKrwIdOF2ZurQeTeCb1qwOyV6h5x6PtnVE3u_v3saP4eTl4Wl8OwlzliRNGAkOcQIJjbOCYcqFpJRxGbGiyDIKBgvBE51xY7qbCpCQShZpRB5FsaZpykbktJ_bHbhs0TdqVreu6laqrg2MJox2kOih3NXeOyzUwtlSu5WioNbO1MaZWgtRAGrjTMkud7Id3mYlmj-pXlIH3PQAdi9-WnTK5xarHI11mDfK1PafFT_vQXoq</recordid><startdate>20000610</startdate><enddate>20000610</enddate><creator>Lell, Bertrand</creator><creator>Faucher, Jean-François</creator><creator>Missinou, Michel Anoumou</creator><creator>Borrmann, Steffen</creator><creator>Dangelmaier, Oliver</creator><creator>Horton, John</creator><creator>Kremsner, Peter G</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TT</scope><scope>0TZ</scope><scope>0U~</scope><scope>3V.</scope><scope>7QL</scope><scope>7QP</scope><scope>7RV</scope><scope>7TK</scope><scope>7U7</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88C</scope><scope>88E</scope><scope>88G</scope><scope>88I</scope><scope>8AF</scope><scope>8AO</scope><scope>8C1</scope><scope>8C2</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>ASE</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FPQ</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K6X</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>KB~</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>S0X</scope></search><sort><creationdate>20000610</creationdate><title>Malaria chemoprophylaxis with tafenoquine: a randomised study</title><author>Lell, Bertrand ; Faucher, Jean-François ; Missinou, Michel Anoumou ; Borrmann, Steffen ; Dangelmaier, Oliver ; Horton, John ; Kremsner, Peter G</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c388t-2540680816bf3e94571134723ffbb10def548ab4dd356f0709732aee4226a1993</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aminoquinolines - administration & dosage</topic><topic>Aminoquinolines - adverse effects</topic><topic>Aminoquinolines - therapeutic use</topic><topic>Antimalarials - administration & dosage</topic><topic>Antimalarials - adverse effects</topic><topic>Antimalarials - therapeutic use</topic><topic>Child</topic><topic>Dose-Response Relationship, Drug</topic><topic>Double-Blind Method</topic><topic>Drug Administration Schedule</topic><topic>Drug therapy</topic><topic>Female</topic><topic>Gabon</topic><topic>Humans</topic><topic>Malaria</topic><topic>Malaria, Falciparum - blood</topic><topic>Malaria, Falciparum - drug therapy</topic><topic>Malaria, Falciparum - prevention & control</topic><topic>Male</topic><topic>Phenanthrenes - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lell, Bertrand</creatorcontrib><creatorcontrib>Faucher, Jean-François</creatorcontrib><creatorcontrib>Missinou, Michel Anoumou</creatorcontrib><creatorcontrib>Borrmann, Steffen</creatorcontrib><creatorcontrib>Dangelmaier, Oliver</creatorcontrib><creatorcontrib>Horton, John</creatorcontrib><creatorcontrib>Kremsner, Peter G</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>News PRO</collection><collection>Pharma and Biotech Premium PRO</collection><collection>Global News & ABI/Inform Professional</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Nursing & Allied Health Database (ProQuest)</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>ProQuest_Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database (Proquest)</collection><collection>Lancet Titles</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>British Nursing Database</collection><collection>British Nursing Index</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>British Nursing Index (BNI) (1985 to Present)</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection (Proquest) (PQ_SDU_P3)</collection><collection>British Nursing Index</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Newsstand Professional</collection><collection>Biological Sciences</collection><collection>Family Health Database (Proquest)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Health Management Database (Proquest)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Psychology Database (ProQuest)</collection><collection>ProQuest research library</collection><collection>ProQuest Science Journals</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>SIRS Editorial</collection><jtitle>The Lancet (British edition)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lell, Bertrand</au><au>Faucher, Jean-François</au><au>Missinou, Michel Anoumou</au><au>Borrmann, Steffen</au><au>Dangelmaier, Oliver</au><au>Horton, John</au><au>Kremsner, Peter G</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Malaria chemoprophylaxis with tafenoquine: a randomised study</atitle><jtitle>The Lancet (British edition)</jtitle><addtitle>Lancet</addtitle><date>2000-06-10</date><risdate>2000</risdate><volume>355</volume><issue>9220</issue><spage>2041</spage><epage>2045</epage><pages>2041-2045</pages><issn>0140-6736</issn><eissn>1474-547X</eissn><coden>LANCAO</coden><abstract>Tafenoquine is an analogue of primaquine with an improved therapeutic and safety profile. It has a long half-life and activity against liver-stage malaria parasites, so may be useful for chemoprophylaxis. In this randomised, double-blind study we assessed the efficacy and safety of tafenoquine in different doses.
2144 individuals aged 12–20 years living in Lambaréné, Gabon, an endemic area for
Plasmodium falciparum malaria, were invited to take part. 535 attended, and 426 eligible participants were randomly assigned tafenoquine (250 mg, 125mg, 62·5 mg, or 31·25 mg) or placebo daily for 3 days. 417 received initial curative treatment with halofantrine, and 410 completed the assigned prophylaxis regimen. During follow-up of 70 days, adverse events were recorded and thick blood smears were examined weekly. The primary and secondary endpoints were the number of individuals with positive blood smears by day 56 and day 77, respectively. Analyses were per-protocol.
Eight positive blood smears were recorded by day 56 (four/82 participants in the placebo group; four/79 tafenoquine 31·25 mg group). By day 77, 34 positive blood smears had been recorded (14/82 placebo; 16/79 tafenoquine 31·25 mg; three/86 tafenoquine 62·5 mg; one/79 tafenoquine 125 mg; none/84 tafenoquine 250 mg). Numbers of adverse events did not differ significantly between the treatment groups.
Tafenoquine is effective and well tolerated. It has the potential to replace currently used drugs for malaria chemoprophylaxis.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>10885356</pmid><doi>10.1016/S0140-6736(00)02352-7</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0140-6736 |
| ispartof | The Lancet (British edition), 2000-06, Vol.355 (9220), p.2041-2045 |
| issn | 0140-6736 1474-547X |
| language | eng |
| recordid | cdi_proquest_journals_199031831 |
| source | Business Source Ultimate; ScienceDirect Freedom Collection 2022-2024 |
| subjects | Adolescent Adult Aminoquinolines - administration & dosage Aminoquinolines - adverse effects Aminoquinolines - therapeutic use Antimalarials - administration & dosage Antimalarials - adverse effects Antimalarials - therapeutic use Child Dose-Response Relationship, Drug Double-Blind Method Drug Administration Schedule Drug therapy Female Gabon Humans Malaria Malaria, Falciparum - blood Malaria, Falciparum - drug therapy Malaria, Falciparum - prevention & control Male Phenanthrenes - therapeutic use |
| title | Malaria chemoprophylaxis with tafenoquine: a randomised study |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-09-22T07%3A27%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Malaria%20chemoprophylaxis%20with%20tafenoquine:%20a%20randomised%20study&rft.jtitle=The%20Lancet%20(British%20edition)&rft.au=Lell,%20Bertrand&rft.date=2000-06-10&rft.volume=355&rft.issue=9220&rft.spage=2041&rft.epage=2045&rft.pages=2041-2045&rft.issn=0140-6736&rft.eissn=1474-547X&rft.coden=LANCAO&rft_id=info:doi/10.1016/S0140-6736(00)02352-7&rft_dat=%3Cproquest_cross%3E55139310%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c388t-2540680816bf3e94571134723ffbb10def548ab4dd356f0709732aee4226a1993%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=199031831&rft_id=info:pmid/10885356&rfr_iscdi=true |